Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
About us Practical matters How to find us D. (Dick) de Zeeuw
University Medical Center Groningen

D. (Dick) de Zeeuw

Professor;Depart of Clinical Pharmacy and Pharmacology
Profile picture of D. (Dick) de Zeeuw
Telephone:
E-mail:
d.de.zeeuw umcg.nl

Publications

Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD

Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status

Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression

Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope

Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes

Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

Press/media

‘Drug rediscovery vraagt bevlogen onderzoekers met creatieve invallen’

Sustainable Development Goals

SDG 3 - Good Health and Well-beingSDG 5 - Gender EqualitySDG 9 - Industry, Innovation, and InfrastructureSDG 10 - Reduced InequalitiesSDG 17 - Partnerships for the Goals

More information about the Sustainable Development Goals.